Aduro Biotech | Engineered Immunotherapy for Cancer

STING Pathway:

Using a Tumor’s Composition to Activate an Immune Response

B-select Antibodies:

Modulating Cancer Immunity

Immunotherapy

Learn how immunotherapies harness a person’s immune system to fight cancer

Clinical Trials

Learn more about Aduro’s clinical programs

Investors

Download the 2017 Annual Report

Recent News

December 12, 2018 Aduro Biotech Data Published in Cell Reports Highlights the Significant Role of the Magnitude of Intratumoral STING Activation by ADU-S100 in Anti-Tumor Immunity

December 03, 2018 Aduro Biotech and Dana-Farber Cancer Institute Present Preclinical Data Supporting Anti-APRIL Antibody BION-1301 for the Treatment of Multiple Myeloma at the 60th American Society of Hematology Annual Meeting and Exposition

November 09, 2018 Aduro Biotech Presents Preliminary Results from Ongoing Phase 1 Trials of STING agonist ADU-S100 (MIW815) in Patients with Advanced Solid Tumors or Lymphomas

Careers

Are you interested in working for a company where interactions are authentic, commitment is high and people excel together?